Intra-Cellular Therapies, Inc. (ITCI) Income Statement Analysis

See more : Mahindra Holidays & Resorts India Limited (MHRIL.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Intra-Cellular Therapies, Inc. (ITCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intra-Cellular Therapies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Intra-Cellular Therapies, Inc. (ITCI)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.intracellulartherapies.com

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	464.37M	249.13M	81.71M	22.53M	60.61K	0.00	245.84K	330.70K	91.36K	577.30K	2.74M	3.12M
Cost of Revenue	33.75M	20.44M	8.03M	1.90M	477.12K	368.67K	79.42M	93.83M	139.63K	21.23M	23.03M	15.49M
Gross Profit	430.63M	228.69M	73.67M	20.64M	-416.51K	-368.67K	-79.17M	-93.50M	-48.26K	-20.65M	-20.29M	-12.37M
Gross Profit Ratio	92.73%	91.79%	90.17%	91.59%	-687.16%	0.00%	-32,205.56%	-28,273.44%	-52.82%	-3,576.82%	-741.34%	-396.68%
Research & Development	180.14M	134.72M	88.85M	65.78M	89.12M	132.17M	79.42M	93.83M	87.72M	21.23M	23.03M	15.49M
General & Administrative	317.66M	272.98M	190.11M	150.06M	64.95M	30.10M	23.67M	24.76M	18.19M	10.34M	5.98M	4.03M
Selling & Marketing	92.20M	85.80M	82.50M	36.30M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	409.86M	358.78M	272.61M	186.36M	64.95M	30.10M	23.67M	24.76M	18.19M	10.34M	5.98M	4.03M
Other Expenses	0.00	-1.18M	-2.10M	-282.23K	0.00	0.00	-245.84K	-330.70K	-60.71K	-29.76K	0.00	0.00
Operating Expenses	590.01M	492.32M	359.36M	251.86M	154.07M	162.27M	103.09M	118.59M	105.91M	31.56M	29.00M	19.52M
Cost & Expenses	623.75M	512.76M	367.40M	253.76M	154.07M	162.27M	103.09M	118.59M	105.91M	31.56M	29.00M	19.52M
Interest Income	20.34M	7.38M	1.57M	4.24M	6.29M	7.14M	4.01M	2.94M	1.02M	303.94K	29.62K	39.00K
Interest Expense	0.00	7.38M	0.00	0.00	0.00	0.00	0.00	36.78K	0.00	7.07K	612.96K	193.50K
Depreciation & Amortization	528.00K	656.00K	533.36K	528.12K	477.12K	368.67K	213.87K	196.87K	139.63K	25.48K	23.25K	47.75K
EBITDA	-158.85M	-262.97M	-285.16M	-230.70M	-153.53M	-161.90M	-102.63M	-115.13M	-104.65M	-30.66M	-26.21M	-16.32M
EBITDA Ratio	-34.21%	-105.82%	-349.65%	-1,026.28%	-254,090.46%	0.00%	-40,203.17%	-34,872.43%	-115,815.85%	-5,314.87%	-957.76%	-523.31%
Operating Income	-159.38M	-263.63M	-285.69M	-231.23M	-154.01M	-162.27M	-102.84M	-118.26M	-105.81M	-30.99M	-26.27M	-16.40M
Operating Income Ratio	-34.32%	-105.82%	-349.65%	-1,026.28%	-254,090.46%	0.00%	-41,832.65%	-35,759.96%	-115,815.85%	-5,367.52%	-959.69%	-526.09%
Total Other Income/Expenses	20.34M	7.38M	1.57M	4.24M	6.29M	7.14M	4.01M	2.90M	1.02M	296.86K	-583.35K	-154.50K
Income Before Tax	-139.04M	-256.25M	-284.12M	-226.99M	-147.72M	-155.13M	-98.83M	-115.36M	-104.79M	-30.69M	-26.85M	-16.56M
Income Before Tax Ratio	-29.94%	-102.86%	-347.73%	-1,007.48%	-243,711.05%	0.00%	-40,203.17%	-34,883.55%	-114,696.75%	-5,316.09%	-981.01%	-531.04%
Income Tax Expense	636.00K	6.00K	5.63K	13.51K	1.60K	1.60K	-1.06M	1.07M	1.60K	1.60K	18.00K	32.92K
Net Income	-139.67M	-256.26M	-284.13M	-227.01M	-147.72M	-155.13M	-97.77M	-116.43M	-104.79M	-30.69M	-26.87M	-16.59M
Net Income Ratio	-30.08%	-102.86%	-347.73%	-1,007.54%	-243,713.69%	0.00%	-39,771.64%	-35,205.79%	-114,698.50%	-5,316.37%	-981.67%	-532.10%
EPS	-1.46	-2.72	-3.50	-3.23	-2.68	-2.84	-2.12	-2.69	-2.91	-1.07	-1.56	-0.75
EPS Diluted	-1.46	-2.72	-3.50	-3.23	-2.68	-2.84	-2.12	-2.69	-2.91	-1.07	-1.56	-0.75
Weighted Avg Shares Out	95.88M	94.05M	81.25M	70.36M	55.19M	54.71M	46.18M	43.24M	36.01M	28.65M	17.22M	22.16M
Weighted Avg Shares Out (Dil)	95.88M	94.05M	81.25M	70.36M	55.19M	54.71M	46.18M	43.24M	36.07M	28.65M	17.26M	22.16M

ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD

December 4, 2024zacks.com

Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

December 3, 2024globenewswire.com

BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced that it has recently submitted a supplemental New Drug Application...

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?

November 29, 2024zacks.com

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

November 19, 2024globenewswire.com

BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and...

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

November 7, 2024globenewswire.com

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Intra-Cellular's schizophrenia drug meets main goal in late-stage trial

November 5, 2024reuters.com

Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.

Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript

October 30, 2024seekingalpha.com

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev...

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

October 30, 2024zacks.com

Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

October 30, 2024zacks.com

Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.25 per share a year ago.